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Background: Microparticles (MP) are small vesicles released from activated cells. MP are increased in Acute Coronary Syndromes (ACS) and have 
been consistently associated with procoagulant activity, yet little is known about their mRNA expression. We sought to characterize mRNA expression 
in MP of ACS and stable angina (SA) patients.
Methods: Venous blood samples were drawn from 32 patients:16 with Non-ST Elevation Myocardial Infarction (NSTEMI) and 16 with SA. Gene 
expression of NSTEMI and SA was compared with a control group of 17 healthy subjects. Total RNA was isolated from circulating MP. mRNA 
expression was examined with a PCR-array system for the atherosclerosis and transcription factors pathways.
Results: 168 genes were investigated. Compared to controls, mRNA expression analysis identified 5 modulated genes for the atherosclerosis 
pathway between NSTEMI and SA ( 3 up- and 2 down-regulated in NSTEMI vs SA). Elastin, Matrix Metalloproteinase -1 (MMP-1) and Selectin showed 
differences in mRNA with a fold change > 5 in NSTEMI vs SA (p<0.05). On the contrary, Angiotensin I Converting Enzyme (ACE) and Neuropeptide Y 
(NPY) mRNA were down-regulated in NSTEMI(p<0.05).The transcription factors-related pathway revealed 8 modulated genes (1 up- and 7 down-
regulated in NSTEMI patients). Androgen receptor (AR), forkhead box 01 (FOX01), were down-regulated with a fold-change > 10 (p<0,05); MYC 
associated factor X (MAX), Nuclear factor of kappa light polypeptide gene (NFKB1), V- relreticuloendotheliosis viral oncogene (RELA) and signal 
transducer and activatorof transcription 4 (STAT4), were down-regulated with a fold expression > 5 in NSTEMI vs SA (p<0,05). General transcription 
factor IIB was up-regulated in NSTEMI with a fold change >3 (p<0,05).
Conclusion: Our study revealed a different MP mRNA profile in NSTEMI patients compared to SA. The higher differences in mRNA expression were 
found among proteins involved in extracellular matrix synthesis or degradation, leukocyte infiltration and inflammation suggesting a role of MP also 
on plaque instability(possibly also as counter regulatory mechanism) and myocardial damage and as a potential novel therapeutic target.
